Last reviewed · How we verify

bupropion and transdermal patch

US Department of Veterans Affairs · Phase 3 active Small molecule

Bupropion is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain.

Bupropion is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain. Used for Major depressive disorder, Smoking cessation.

At a glance

Generic namebupropion and transdermal patch
SponsorUS Department of Veterans Affairs
Drug classNorepinephrine-dopamine reuptake inhibitor
TargetNorepinephrine transporter, Dopamine transporter
ModalitySmall molecule
Therapeutic areaMental health, Smoking cessation
PhasePhase 3

Mechanism of action

This action is thought to contribute to its antidepressant and smoking cessation effects. The transdermal patch formulation allows for a more consistent release of the drug into the bloodstream.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: